ZA97858B - Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant. - Google Patents
Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant.Info
- Publication number
- ZA97858B ZA97858B ZA9700858A ZA97858A ZA97858B ZA 97858 B ZA97858 B ZA 97858B ZA 9700858 A ZA9700858 A ZA 9700858A ZA 97858 A ZA97858 A ZA 97858A ZA 97858 B ZA97858 B ZA 97858B
- Authority
- ZA
- South Africa
- Prior art keywords
- granulocyte
- adjuvant
- stimulating factor
- colony stimulating
- macrophage colony
- Prior art date
Links
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title abstract 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/598,909 US6096313A (en) | 1996-02-09 | 1996-02-09 | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA97858B true ZA97858B (en) | 1997-08-04 |
Family
ID=24397438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9700858A ZA97858B (en) | 1996-02-09 | 1997-02-03 | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant. |
Country Status (12)
Country | Link |
---|---|
US (1) | US6096313A (xx) |
EP (1) | EP0932411B1 (xx) |
JP (1) | JP2000506518A (xx) |
AT (1) | ATE243525T1 (xx) |
AU (1) | AU723147B2 (xx) |
CA (1) | CA2244867C (xx) |
DE (1) | DE69723092T2 (xx) |
DK (1) | DK0932411T3 (xx) |
ES (1) | ES2196305T3 (xx) |
PT (1) | PT932411E (xx) |
WO (1) | WO1997028816A1 (xx) |
ZA (1) | ZA97858B (xx) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20030235557A1 (en) * | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7901693B2 (en) * | 1998-09-30 | 2011-03-08 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7063854B1 (en) * | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
US7144581B2 (en) * | 2000-10-09 | 2006-12-05 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7329410B1 (en) | 1998-09-30 | 2008-02-12 | Corixa Corporation | Compositions and method for WT1 specific immunotherapy |
US7115272B1 (en) | 1998-09-30 | 2006-10-03 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US20030039635A1 (en) * | 1998-09-30 | 2003-02-27 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7655249B2 (en) * | 1998-09-30 | 2010-02-02 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
TR200103266T2 (tr) * | 1999-05-13 | 2002-01-21 | American Cyanamid Company | Yardımcı kombinasyon formülasyonları |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
AU1013701A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
TW581709B (en) | 1999-10-22 | 2004-04-01 | Asahi Kasei Corp | Heat-resistant microporous film |
SG143058A1 (en) * | 2000-08-11 | 2008-06-27 | Favrille Inc | Method and composition for altering a t cell mediated pathology |
US6911204B2 (en) | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
EE200300172A (et) * | 2000-11-10 | 2003-06-16 | Wyeth Holdings Corporation | Antigeenne kompositsioon ja adjuvantsegu |
US7553494B2 (en) * | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US7459085B2 (en) * | 2002-10-18 | 2008-12-02 | Asahi Kasei Medical Co., Ltd. | Microporous hydrophilic membrane |
CN103288920B (zh) | 2003-01-30 | 2015-08-12 | 苏瓦克有限公司 | 存活蛋白衍生肽及其用途 |
EP1691824B1 (en) | 2003-11-19 | 2009-03-11 | Survac ApS | Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients |
US20050260217A1 (en) * | 2004-03-04 | 2005-11-24 | Corixa Corporation | Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
AU2006209951B2 (en) | 2005-02-04 | 2011-04-14 | Survac Aps | Survivin peptide vaccine |
ES2330013T3 (es) * | 2005-09-05 | 2009-12-03 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas. |
CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
GB2432723B (en) * | 2005-11-25 | 2010-12-08 | Seiko Epson Corp | Electrochemical cell and method of manufacture |
GB2432722A (en) * | 2005-11-25 | 2007-05-30 | Seiko Epson Corp | Electrochemical cell and method of manufacture |
GB2432721B (en) * | 2005-11-25 | 2011-06-22 | Seiko Epson Corp | Electrochemical cell structure and method of fabrication |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
KR101167392B1 (ko) * | 2007-07-27 | 2012-07-19 | 이매틱스 바이오테크놀로지스 게엠베하 | 종양 관련 펩티드의 조성물 및 관련된 항암 백신 |
JP5731198B2 (ja) | 2007-09-27 | 2015-06-10 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用 |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
AU2009253539B2 (en) | 2008-04-17 | 2014-03-20 | Io Biotech Aps | Indoleamine 2, 3-dioxygenase based immunotherapy |
JP5715051B2 (ja) | 2008-06-05 | 2015-05-07 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物 |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2012062873A2 (en) | 2010-11-10 | 2012-05-18 | Laboratorios Del Dr. Esteve, S.A. | Highly immunogenic hiv p24 sequences |
EP2492279A1 (en) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Rapid immunogen selection method using lentiviral display |
EP2546358A1 (en) | 2011-07-15 | 2013-01-16 | Laboratorios Del. Dr. Esteve, S.A. | Methods and reagents for efficient control of HIV progression |
US10105435B2 (en) | 2011-10-06 | 2018-10-23 | Immunovaccine Technologies Inc. | Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof |
WO2013056716A1 (en) | 2011-10-17 | 2013-04-25 | Herlev Hospital | Pd-l1 based immunotherapy |
WO2013060328A1 (en) | 2011-10-26 | 2013-05-02 | Herlev Hospital | Ikb based immunotherapy |
EP2606897A1 (en) | 2011-12-22 | 2013-06-26 | Laboratorios Del. Dr. Esteve, S.A. | Methods and compositions for the treatment of diseases caused by enveloped viruses |
EP2617434A1 (en) | 2012-01-20 | 2013-07-24 | Laboratorios Del. Dr. Esteve, S.A. | HIV-1 integrase deficient immunogens and methods for loading dendritic cells with said immunogens |
EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
EP2698377A1 (en) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Enhanced rapid immunogen selection method for HIV gp120 variants |
EP2703482A1 (en) | 2012-09-04 | 2014-03-05 | Laboratorios Del. Dr. Esteve, S.A. | VSV-HIV viral particles lacking reverse transcriptase functionality and therapeutic applications thereof |
ES2639855T3 (es) | 2013-12-23 | 2017-10-30 | Exchange Imaging Technologies Gmbh | Nanopartícula conjugada a péptidos de unión a CD44 |
EP3919074A1 (en) | 2014-09-17 | 2021-12-08 | IO Biotech ApS | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof |
US11298413B2 (en) | 2015-09-16 | 2022-04-12 | Io Biotech Aps | Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof |
EP3147364A1 (en) | 2015-09-28 | 2017-03-29 | Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS) | Antiviral agents comprising an oligonucleotide-lipid conjugate forming g-quadruplex |
AU2017276498A1 (en) | 2016-06-10 | 2019-01-03 | Io Biotech Aps | CALR and JAK2 vaccine compositions |
EP3275462A1 (en) | 2016-07-27 | 2018-01-31 | Fundació Privada Institut de Recerca de la SIDA-Caixa | Virus-like particles with high-density coating for the production of neutralizing antibodies |
CA3141454A1 (en) | 2019-05-22 | 2020-11-26 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
WO2022017895A1 (en) | 2020-07-21 | 2022-01-27 | Rhovac Aps | Treatment of residual disease |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5679356A (en) * | 1992-07-08 | 1997-10-21 | Schering Corporation | Use of GM-CSF as a vaccine adjuvant |
US5519117A (en) * | 1992-12-22 | 1996-05-21 | Ludwig Institute For Cancer Research | Isolated, tyrosinase derived peptides and uses thereof |
US5620886A (en) * | 1993-03-18 | 1997-04-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
US5478556A (en) * | 1994-02-28 | 1995-12-26 | Elliott; Robert L. | Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor |
US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
AU3889997A (en) * | 1996-08-16 | 1998-03-06 | Johns Hopkins University School Of Medicine, The | Melanoma cell lines expressing shared immunodominant melanoma antigens nd methods of using same |
-
1996
- 1996-02-09 US US08/598,909 patent/US6096313A/en not_active Expired - Lifetime
-
1997
- 1997-01-28 AU AU17552/97A patent/AU723147B2/en not_active Expired
- 1997-01-28 CA CA002244867A patent/CA2244867C/en not_active Expired - Lifetime
- 1997-01-28 EP EP97904876A patent/EP0932411B1/en not_active Expired - Lifetime
- 1997-01-28 DE DE69723092T patent/DE69723092T2/de not_active Expired - Lifetime
- 1997-01-28 WO PCT/US1997/001249 patent/WO1997028816A1/en active IP Right Grant
- 1997-01-28 PT PT97904876T patent/PT932411E/pt unknown
- 1997-01-28 AT AT97904876T patent/ATE243525T1/de active
- 1997-01-28 JP JP9528538A patent/JP2000506518A/ja not_active Ceased
- 1997-01-28 ES ES97904876T patent/ES2196305T3/es not_active Expired - Lifetime
- 1997-01-28 DK DK97904876T patent/DK0932411T3/da active
- 1997-02-03 ZA ZA9700858A patent/ZA97858B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DK0932411T3 (da) | 2003-08-18 |
ES2196305T3 (es) | 2003-12-16 |
JP2000506518A (ja) | 2000-05-30 |
US6096313A (en) | 2000-08-01 |
DE69723092D1 (de) | 2003-07-31 |
AU723147B2 (en) | 2000-08-17 |
AU1755297A (en) | 1997-08-28 |
PT932411E (pt) | 2003-11-28 |
EP0932411A4 (en) | 2001-09-26 |
ATE243525T1 (de) | 2003-07-15 |
DE69723092T2 (de) | 2003-12-18 |
CA2244867C (en) | 2003-09-09 |
EP0932411A1 (en) | 1999-08-04 |
WO1997028816A1 (en) | 1997-08-14 |
CA2244867A1 (en) | 1997-08-14 |
EP0932411B1 (en) | 2003-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA97858B (en) | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant. | |
MY119403A (en) | Novel compounds with analgesic effect. | |
CA2068324A1 (en) | Metal-peptide compositions and methods for stimulating hair growth | |
MY122383A (en) | Cyclic boroproline compounds | |
MX9603560A (es) | Composiciones de prostaglandinas estables en almacenamiento. | |
EP1428821A8 (en) | Piperidin-4-yl amines with analgesic effect | |
AU595192B2 (en) | Benzonaphthalene derivatives, a process for their preparation and their use in therapeutic and cosmetic compositions | |
CA2075060A1 (en) | Novel vehicle gases and their use in medical preparations | |
PL319833A1 (en) | Compounds and composition for carrying active media | |
GR3000495T3 (en) | Use of beerdraff for the preparation of medicinal and cosmetic preparations | |
ATE188965T1 (de) | Neue pyrazincarboxamidderivate, ihre herstellung und ihre verwendung in arzneimitteln | |
NZ301645A (en) | (R)-(-)-methyl phenyl oxazolidinone derivatives, pharmaceutical preparations and use for treating TNF stimulated diseases | |
MY109990A (en) | Microfluidised particles of atovaquone and pharmaceutical preparation thereof | |
MX9501848A (es) | Nuevos compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos. | |
EP1535929A3 (en) | Megakaryocyte stimulating factors | |
GB9604577D0 (en) | Serum cholesterol lowering agent | |
PL316656A1 (en) | Free halophantrin base for use in treating marsh-fever and compositions containing same | |
IL150125A0 (en) | Novel compounds | |
NZ511445A (en) | Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects | |
AU1815899A (en) | Method and composition to enhance the efficacy of a vaccine using chemokines | |
NZ240612A (en) | Dietary compositions containing psyllium fibre and almond paste | |
EP0167995A3 (en) | (pyrrol-1-yl)-phenyl-dihydropyridazinones, their preparation and use | |
ES8703456A1 (es) | Procedimiento para preparar derivados de nitrofurano | |
UA42797C2 (uk) | Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання | |
ZA874470B (en) | New tetrahydrobenzothiazoles,and the preparation and use thereof |